AnaptysBio (NASDAQ:ANAB) Trading Down 5.9%

AnaptysBio, Inc. (NASDAQ:ANAB)’s share price traded down 5.9% on Thursday . The company traded as low as $20.10 and last traded at $20.20. 214,966 shares traded hands during trading, a decline of 31% from the average session volume of 311,290 shares. The stock had previously closed at $21.47.

Analyst Ratings Changes

ANAB has been the topic of several recent analyst reports. BTIG Research assumed coverage on shares of AnaptysBio in a research note on Monday, February 26th. They issued a “buy” rating and a $55.00 target price on the stock. Piper Sandler started coverage on AnaptysBio in a research note on Friday, February 16th. They set an “overweight” rating and a $80.00 price objective for the company. Leerink Partnrs restated an “outperform” rating on shares of AnaptysBio in a research report on Tuesday. JPMorgan Chase & Co. lowered their price target on AnaptysBio from $30.00 to $28.00 and set a “neutral” rating on the stock in a report on Monday, April 1st. Finally, SVB Leerink began coverage on AnaptysBio in a research report on Tuesday. They set an “outperform” rating and a $47.00 price target for the company. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, AnaptysBio has a consensus rating of “Moderate Buy” and a consensus target price of $46.22.

AnaptysBio Stock Performance

The stock has a 50-day simple moving average of $23.25 and a two-hundred day simple moving average of $20.56.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Monday, March 11th. The biotechnology company reported ($1.59) EPS for the quarter, beating the consensus estimate of ($1.74) by $0.15. The firm had revenue of $9.01 million for the quarter, compared to analyst estimates of $3.28 million. AnaptysBio had a negative return on equity of 119.42% and a negative net margin of 953.66%. As a group, equities research analysts forecast that AnaptysBio, Inc. will post -6.17 EPS for the current fiscal year.

Insider Buying and Selling at AnaptysBio

In other news, CFO Dennis Mulroy sold 3,065 shares of the business’s stock in a transaction that occurred on Tuesday, January 30th. The shares were sold at an average price of $23.63, for a total value of $72,425.95. Following the completion of the sale, the chief financial officer now directly owns 964 shares in the company, valued at approximately $22,779.32. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, insider Eric J. Loumeau sold 5,000 shares of the stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.00, for a total transaction of $125,000.00. Following the completion of the sale, the insider now directly owns 3,240 shares in the company, valued at approximately $81,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Dennis Mulroy sold 3,065 shares of the firm’s stock in a transaction that occurred on Tuesday, January 30th. The stock was sold at an average price of $23.63, for a total value of $72,425.95. Following the transaction, the chief financial officer now owns 964 shares in the company, valued at $22,779.32. The disclosure for this sale can be found here. Insiders have sold 157,005 shares of company stock worth $3,586,199 over the last ninety days. Insiders own 35.50% of the company’s stock.

Institutional Trading of AnaptysBio

A number of institutional investors have recently made changes to their positions in ANAB. Swiss National Bank raised its holdings in AnaptysBio by 7.9% during the 1st quarter. Swiss National Bank now owns 42,300 shares of the biotechnology company’s stock valued at $1,047,000 after buying an additional 3,100 shares during the last quarter. MetLife Investment Management LLC raised its stake in shares of AnaptysBio by 57.0% during the first quarter. MetLife Investment Management LLC now owns 11,043 shares of the biotechnology company’s stock valued at $273,000 after acquiring an additional 4,009 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of AnaptysBio by 11.0% during the first quarter. Dimensional Fund Advisors LP now owns 891,851 shares of the biotechnology company’s stock worth $22,064,000 after purchasing an additional 88,457 shares during the period. Ergoteles LLC bought a new stake in shares of AnaptysBio in the first quarter worth about $479,000. Finally, Charles Schwab Investment Management Inc. increased its holdings in AnaptysBio by 4.3% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 142,131 shares of the biotechnology company’s stock valued at $3,517,000 after purchasing an additional 5,819 shares during the period.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.